Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy
about
The roles of lipid and glucose metabolism in modulation of β-amyloid, tau, and neurodegeneration in the pathogenesis of Alzheimer diseaseStatins promote the degradation of extracellular amyloid {beta}-peptide by microglia via stimulation of exosome-associated insulin-degrading enzyme (IDE) secretionPossible modification of Alzheimer's disease by statins in midlife: interactions with genetic and non-genetic risk factorsTargeting Abeta and tau in Alzheimer's disease, an early interim reportAssociation among amyloid plaque, lipid, and creatine in hippocampus of TgCRND8 mouse model for Alzheimer disease.A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease.Animal models in the drug discovery pipeline for Alzheimer's diseaseAtorvastatin in improvement of cognitive impairments caused by amyloid β in mice: involvement of inflammatory reactionAtorvastatin attenuates the production of IL-1β, IL-6, and TNF-α in the hippocampus of an amyloid β1-42-induced rat model of Alzheimer's diseaseDetrimental effects of diet-induced obesity on τ pathology are independent of insulin resistance in τ transgenic mice.APP/PS1 mice overexpressing SREBP-2 exhibit combined Aβ accumulation and tau pathology underlying Alzheimer's disease.Pharmacotherapy of traumatic brain injury: state of the science and the road forward: report of the Department of Defense Neurotrauma Pharmacology Workgroup.The role of tau in Alzheimer's disease and related disorders.Mechanisms and clinical evidence of the pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in central nervous system disorders: a comprehensive review.What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research.Molecular basis of etiological implications in Alzheimer's disease: focus on neuroinflammation.Novel disease-modifying therapeutics for the treatment of Alzheimer's disease.Insulin Resistance and Neurodegeneration: Progress Towards the Development of New Therapeutics for Alzheimer's Disease.Inhibition of neuronal cholesterol biosynthesis with lovastatin leads to impaired synaptic vesicle release even in the presence of lipoproteins or geranylgeraniol.Atorvastatin prevents Aβ oligomer-induced neurotoxicity in cultured rat hippocampal neurons by inhibiting Tau cleavageStatin treatment affects cytokine release and phagocytic activity in primary cultured microglia through two separable mechanisms.Untangling Neurons With Endothelial Nitric Oxide.The impact of cholesterol, DHA, and sphingolipids on Alzheimer's disease.Antidiabetic Polypill Improves Central Pathology and Cognitive Impairment in a Mixed Model of Alzheimer's Disease and Type 2 Diabetes.Age, vascular health, and Alzheimer disease biomarkers in an elderly sample.Isoprenoids and protein prenylation: implications in the pathogenesis and therapeutic intervention of Alzheimer's disease.
P2860
Q26777969-31A2CB45-56F5-4A0C-9BF2-0985F587AB3CQ28294279-386FEAC4-B4DD-4589-8EF2-7D64835BDBC4Q30814231-B02B2718-6222-4853-95B1-DEEB055FFC61Q33829008-3F5EF7DD-51E0-4ABB-831B-7EFD4E813A32Q34181241-C45ADBF0-5AFA-4EEF-9A65-E4570BA6ED94Q35144361-25D6A908-FCD6-481E-9D4E-280B278C7E99Q35589962-E670A93B-CFC7-4AB1-B290-23CB77BB2EE4Q35914692-C0927619-D658-4E15-ACDD-EE44423D5F8CQ36584677-E00C7388-C793-40DE-883D-81B691160104Q36796015-8322F394-A785-47E0-9733-0456C60C56E6Q37078850-B54C5259-FF1C-46DF-9191-ED6F15397A35Q37508249-C932CED1-11A9-41E3-AA13-520A2686FD94Q37765632-2AAA0BAB-36F5-4228-B0CF-3303984C1C9BQ38020536-BAA8B8BA-1001-4DA1-9C38-67A06D1F3179Q38034060-E1E1B9BD-6F57-4EFC-9470-12253D75688FQ38082670-EFE5B54E-8C1A-4EB7-BB8E-EA83069C34DCQ38127470-C285AFEE-F042-4C73-961C-43306D01E4CDQ39042377-E552F6BB-4C3E-4F26-B259-2671AFBE4AC8Q39478056-AABB0947-7E24-470A-A2F6-F0C9C18D29EDQ40378989-981B7456-B22B-4206-8448-309C498215BFQ41848796-45B95ECB-2AD8-4E47-842A-460CEF994CB9Q42771236-7C800A77-DF8B-4B5E-AE86-904C33B0CC3CQ43988916-3F02B14D-14A4-4A00-888B-C5B43CCF891BQ47336486-72EE3897-9BBE-4E84-9A4A-60E4201E117BQ47653348-942542AD-463F-4AD6-A6E0-E98B3E084450Q54223105-D562B6B0-535F-4262-9DAC-A617A890B8EC
P2860
Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy
description
2009 nî lūn-bûn
@nan
2009 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մարտին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy
@ast
Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy
@en
Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy
@nl
type
label
Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy
@ast
Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy
@en
Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy
@nl
prefLabel
Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy
@ast
Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy
@en
Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy
@nl
P2093
P2860
P1476
Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy
@en
P2093
Athanassios Lourbopoulos
David Rosenmann
Hanna Rosenmann
Moran Boimel
Nikolaos Grigoriadis
Oded Abramsky
Olga Touloumi
P2860
P304
P356
10.1097/NEN.0B013E31819AC3CB
P407
P577
2009-03-01T00:00:00Z